John Groetelaars
Share |


John Groetelaars

EVP & President at BD

John P. Groetelaars was appointed Executive Vice President and President of the BD Interventional segment upon the acquisition of C.R. Bard by Becton, Dickinson and Company.  As EVP & President, John’s responsibilities include the global strategic, operational and commercial performance of the Interventional segment and will be accountable for delivering the segment’s global financial performance and innovation platform. The Interventional segment is comprised of Peripheral Intervention, Urology & Critical Care and Surgery Businesses. 


Prior to the acquisition, John joined Bard in 2008 as Vice President and General Manager, Davol Inc. in Warwick, RI. John was President of Davol from 2009 to 2013.  In July 2013, he was promoted to Group Vice President and assumed additional responsibilities by adding China, Asia and Australia/New Zealand to his responsibilities for Davol. In July 2015, he was promoted to Group President and added Bard Access Systems to his responsibilities. Prior to joining Bard, John held positions of increasing responsibility with Boston Scientific Corporation from 2001 until joining Bard.  John served as General Manager and Vice President for Canada and then later for the UK, Ireland and Nordic Regions.  Prior to Boston Scientific, John held positions in general management, marketing, business development and sales with Guidant Corporation from 1993 and with Eli Lilly from 1991.


John received a BS in Mechanical Engineering from Kettering University in Michigan and an MBA from Columbia University in New York.